Thus, non-nucleotide inhibitors have been considered as an alternative approach for drug development
This depletion can manifest itself in ways that might include impaired nutrient absorption and assimilation, gut, lung, eye, blood, skin, and brain issues, keloid scarring, mitochondrial stress for lower energy output, DNA mutation, mass oxidation, and free radical overload (1)
Figure 1 Exposure to cagrilintide failed to reduce body weight or fat mass in diet-induced obese (DIO) mice
More recently, their anti-inflammatory, cardioprotective, and neuroprotective properties have been explored in conditions such as cardiovascular disease (24), non-alcoholic fatty liver disease (25), osteoarthritis (26), rheumatoid arthritis (27), Alzheimers (28), and Parkinsons disease (29)
Nagler, A
Ribas GS et al